3,781 followers
RT @CHEyork: The clinical and cost-effectiveness of Inotuzumab Ozogamicin for the treatment of adult relapsed or refractory B-cell acute ly…
RT @CHEyork: The clinical and cost-effectiveness of Inotuzumab Ozogamicin for the treatment of adult relapsed or refractory B-cell acute ly…
The clinical and cost-effectiveness of Inotuzumab Ozogamicin for the treatment of adult relapsed or refractory B-cell acute lymphoblastic Leukaemia: An evidence review group evaluation of a NICE single technology appraisal. https://t.co/iHrdpxvF9o
#HealthEconJA The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal https://t.co/o8rT8h